Table 2 Basic characteristics and quality evaluation of the included literature
From: Prevalence and factors of urinary incontinence among postpartum: systematic review and meta-analysis
Author | Years | Countries | Type of research | follow-up time (mouth) | Types of UI | Sample size (Cases) | Number of urinary incontinences (Cases) | Incidence of urinary incontinence (%) | Influencing factorsa | Quality evaluation |
|---|---|---|---|---|---|---|---|---|---|---|
Yang X [20] | 2004 | China | Cross-sectional studies | 12 | ALL | 548 | 167 | 30.47 | 1、4 | AHRQ score = 5 |
Yan MQ [21] | 2016 | China | Cross-sectional studies | / | ALL | 237 | 103 | 43.46 | 1、2、3、9 | AHRQ score = 6 |
Wu LY [22] | 2015 | China | Cross-sectional studies | 1.5–2 | SUI | 94 | 19 | 20.21 | 1、6、9、10 | AHRQ score = 7 |
Xiong YY [23] | 2021 | China | Cross-sectional studies | 1.5–2 | SUI | 188 | 83 | 44.15 | 1、7 | AHRQ score = 7 |
Wen L [24] | 2014 | China | Cross-sectional studies | 6 | ALL | 2426 | 154 | 6.35 | 1、6、8、11 | AHRQ score = 7 |
Leroy, LD [25] | 2016 | Brazil | Cross-sectional studies | / | ALL | 344 | 77 | 22.38 | 6 | AHRQ score = 7 |
Wang SJ [26] | 2022 | China | Cross-sectional studies | / | SUI | 449 | 65 | 14.48 | 1、4、5 | AHRQ score = 8 |
Di HY [27] | 2021 | China | Cross-sectional studies | / | SUI | 258 | 39 | 15.12 | 2、4、6、11 | AHRQ score = 8 |
Huang XF [28] | 2016 | China | Cross-sectional studies | 1.5–2 | ALL | 1340 | 345 | 25.75 | 1、6 | AHRQ score = 8 |
Cheng H [29] | 2016 | China | Cross-sectional studies | 1.5–2 | SUI | 912 | 360 | 39.47 | 1 | AHRQ score = 8 |
Yu J [30] | 2022 | China | Cross-sectional studies | / | SUI | 1600 | 336 | 21.00 | 1、2、4、7、12 | AHRQ score = 8 |
He H [31] | 2016 | China | Case–control study | 1.5 | SUI | 200 | 100 | / | 1、4、6、8 | NOS score = 6 |
Guo Zl [32] | 2018 | China | Cohort Studies | 2 | SUI | 114 | 12 | 10.53 | 1、6、9、10 | NOS score = 6 |
Wang Q [8] | 2019 | China | Cross-sectional studies | 1.5–3 | SUI | 1027 | 303 | 29.50 | 1、2、3、7 | AHRQ score = 8 |
Xiang JC [33] | 2020 | China | Cross-sectional studies | 1.5–3.5 | SUI | 684 | 245 | 35.82 | 1、4、12 | AHRQ score = 8 |
Wang D [34] | 2018 | China | Cross-sectional studies | 1–1.5 | SUI | 90 | 18 | 20.00 | 1、6、9、10 | AHRQ score = 8 |
Gao JJ [35] | 2021 | China | Cross-sectional studies | / | SUI | 612 | 196 | 32.03 | 1、7 | AHRQ score = 8 |
Liu J [36] | 2015 | China | Cross-sectional studies | / | SUI | 79 | 41 | 51.90 | 3、4 | AHRQ score = 8 |
Zeng JH [37] | 2017 | China | Cross-sectional studies | 1.5–2.5 | SUI | 2163 | 836 | 38.65 | 2、3 | AHRQ score = 8 |
Svare J [38] | 2014 | Denmark | Cross-sectional studies | 12 | ALL | 745 | 172 | 23.09 | 6、9 | AHRQ score = 8 |
Chen Q [39] | 2013 | China | Cross-sectional studies | 1.5–2 | SUI | 82 | 13 | 15.85 | 1、4、6 | AHRQ score = 8 |
Cheng, H [40] | 2022 | China | Cross-sectional studies | 1.5 | SUI | 360 | 90 | 25.00 | 1、3 | AHRQ score = 8 |
Chang, S.D [41] | 2023 | China | Cross-sectional studies | 12 | SUI | 303 | 50 | 16.50 | 2、9 | AHRQ score = 8 |
Xiong YY [42] | 2022 | China | Cross-sectional studies | / | SUI | 500 | 199 | 39.80 | 1、3 | AHRQ score = 9 |
Wan L [43] | 2021 | China | Case–control study | 1.5 | SUI | 142 | 70 | 49.30 | 1、4、7 | NOS score = 6 |
Wang XY [44] | 2019 | China | Cross-sectional studies | 1.5–2 | SUI | 141 | 81 | 57.45 | 4、9 | AHRQ score = 9 |
Zhang YY [45] | 2021 | China | Cross-sectional studies | 1.5–2 | SUI | 811 | 71 | 8.75 | 1、2、5、9、12 | AHRQ score = 9 |
Yang XE [46] | 2020 | China | Cross-sectional studies | 1.5–2 | SUI | 475 | 55 | 11.58 | 1、3、5、7、8 | AHRQ score = 9 |
Zhao X [47] | 2019 | China | Cross-sectional studies | 1.5–2 | SUI | 940 | 92 | 9.79 | 1、3、4、7、8、9 | AHRQ score = 9 |
Liang Y [48] | 2020 | China | Cross-sectional studies | 1.5–2 | ALL | 717 | 120 | 16.74 | 1、2 | AHRQ score = 9 |
Shi W [49] | 2019 | China | Cross-sectional studies | 1.5 | ALL | 9550 | 1483 | 15.53 | 2、3、4、6、7、9、11 | AHRQ score = 9 |
Zhong, R [50] | 2022 | China | Cohort Studies | 12 | SUI | 172 | 52 | 30.23 | 2、6 | NOS score = 7 |